BioNTech's (BNTX) Buy Rating Reaffirmed at HC Wainwright

BioNTech (NASDAQ:BNTX - Get Free Report)'s stock had its "buy" rating reiterated by analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $150.00 price target on the stock. HC Wainwright's price objective indicates a potential upside of 47.25% from the company's previous close.

BNTX has been the topic of several other reports. Bank of America lifted their price target on BioNTech from $125.00 to $150.00 and gave the company a "buy" rating in a research report on Monday, September 16th. TD Cowen cut their price objective on BioNTech from $132.00 to $122.00 and set a "hold" rating for the company in a research report on Tuesday, November 5th. JPMorgan Chase & Co. cut their target price on BioNTech from $125.00 to $124.00 and set a "neutral" rating on the stock in a research report on Monday, November 4th. The Goldman Sachs Group raised BioNTech from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $90.00 to $137.00 in a research note on Friday, November 8th. Finally, UBS Group lifted their price target on BioNTech from $97.00 to $131.00 and gave the company a "neutral" rating in a report on Wednesday, September 18th. Four analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, BioNTech presently has a consensus rating of "Moderate Buy" and a consensus price target of $137.54.

BioNTech Trading Up 2.2 %

BNTX traded up $2.15 during trading on Monday, hitting $101.87. The company's stock had a trading volume of 1,162,915 shares, compared to its average volume of 806,952. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49. The firm's 50 day moving average price is $113.54 and its 200-day moving average price is $97.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The stock has a market cap of $24.42 billion, a PE ratio of -47.49 and a beta of 0.26.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same period last year, the company earned $0.73 EPS. The firm's quarterly revenue was up 38.9% on a year-over-year basis. On average, analysts expect that BioNTech will post -3.68 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

Institutional investors and hedge funds have recently made changes to their positions in the business. Baillie Gifford & Co. raised its position in shares of BioNTech by 0.4% during the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company's stock valued at $986,750,000 after purchasing an additional 31,773 shares during the period. FMR LLC grew its holdings in BioNTech by 797.8% during the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company's stock valued at $748,243,000 after buying an additional 5,598,190 shares in the last quarter. Capital World Investors lifted its holdings in shares of BioNTech by 0.5% in the first quarter. Capital World Investors now owns 943,116 shares of the company's stock worth $87,002,000 after buying an additional 4,369 shares in the last quarter. Deerfield Management Company L.P. Series C grew its stake in BioNTech by 4.3% during the second quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company's stock valued at $47,734,000 after acquiring an additional 24,426 shares in the last quarter. Finally, Candriam S.C.A. increased its holdings in BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company's stock valued at $46,526,000 after acquiring an additional 418,695 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.